Tag Archives: Some

Chi-Med, AstraZeneca’s savolitinib helps some Tagrisso-resistant EGFR lung cancer patients

ATLANTA—AstraZeneca’s Tagrisso has taken the EGFR lung cancer market by storm, but some patients develop resistance to the therapy. Enter Chi-Med. The Chinese company Sunday rolled out phase 1b results showing that certain treatment-resistant patients showed improvement after receiving a combination of Tagrisso, which targets the EGFR gene mutation, and Chi-Med’s savolitinib, a MET inhibitor… Read More »

Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company

Payer coverage is key to Novartis’ plan to get Kymriah going, and the company is going to be getting some more of that. England’s cost watchdog, the National Institute for Health and Care Excellence (NICE), has recommended the CAR-T med to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) through its Cancer… Read More »